戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ated PDE5A1 catalytic domain in complex with vardenafil.
2  effect on affinity for cAMP, sildenafil, or vardenafil.
3 .60, 1.9 +/- 0.37, and 2.7 +/- 0.25 nM); and vardenafil (0.091 +/- 0.031, 0.38 +/- 0.07, 0.27 +/- 0.0
4                            At peak exercise, vardenafil 10 mg did not alter blood pressure, heart rat
5                         Relative to placebo, vardenafil 10 mg did not alter exercise treadmill time (
6                                              Vardenafil 10 mg did not impair the ability of patients
7 ertional angina due to ischemic CAD received vardenafil 10 mg or placebo, followed by ETT (5 to 10 me
8 ed mild major depression received placebo or vardenafil, 10 mg/day, for 4 weeks, with the option to t
9                                The effect of vardenafil, a potent and highly selective phosphodiester
10                                              Vardenafil, a potent PDE5 inhibitor (K(i) = 0.2 nM), was
11  method was applied in a formal synthesis of vardenafil, a well-known representative of this class of
12                               Sildenafil and vardenafil affinity were not significantly affected in P
13 binding affinity of [(3)H]tadalafil or [(3)H]vardenafil, an effect presumably mediated by cGMP bindin
14                    Studies of sildenafil and vardenafil analogs demonstrated that higher potency of v
15 cGMP signaling pathways, FASS-LTP identified vardenafil and Bay-73-6691 (phosphodiesterase-5 and -9 i
16 pecially for vardenafil, and that binding of vardenafil and sildenafil differs substantially.
17 nding of two phosphodiesterase 5 inhibitors, vardenafil and sildenafil, to the retina rod phosphodies
18 ing PDE5Is, including sildenafil, tadalafil, vardenafil, and avanafil.
19 erase-5 (PDE5) is the target for sildenafil, vardenafil, and tadalafil, which are drugs for treatment
20 major determinant of potency, especially for vardenafil, and that binding of vardenafil and sildenafi
21 PDE5) inhibitors (sildenafil, tadalafil, and vardenafil) are agents currently in clinical use for non
22 phase binds selectively to a PDE5 inhibitor, Vardenafil, as well as its molecular variant, but not to
23  GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a
24                                   Both [(3)H]vardenafil binding and hydrolytic activity of transducin
25 f membrane-associated PDE6 holoenzyme, [(3)H]vardenafil binding increases in proportion to the extent
26 e filtration assay we used to quantify [(3)H]vardenafil binding to PDE6 required histone II-AS to sta
27                Under these conditions, [(3)H]vardenafil binds stoichiometrically to both the alpha- a
28 amma1-60 binding to the GAF domain increased vardenafil but not cGMP affinity, indicating that substr
29         It is noteworthy that the binding of vardenafil causes loss of the divalent metal ions that h
30 erectile function domain score was 22.9 with vardenafil compared to 14.9 with placebo.
31 the conformation of the H-loop in the PDE5A1-vardenafil complex is different from those of any known
32 otherapy response in ependymoma patients and vardenafil, currently used to treat paediatric pulmonary
33  In addition, the molecular configuration of vardenafil differs from that of sildenafil when bound to
34 gy of tadalafil to mouse PDE5A compared with vardenafil, due to steric clashes of vardenafil with a s
35                   Sildenafil, tadalafil, and vardenafil each competitively inhibit cGMP hydrolysis by
36      PDE5 inhibitors (sildenafil, tadalafil, vardenafil, etc.) are first-line treatments for erectile
37                                        [(3)H]vardenafil fails to bind to either the PDE6 holoenzyme o
38             The HAM-D score was lower in the vardenafil group (7.9) than in the placebo group (10.1).
39  each inhibitor, and relative potencies were vardenafil >> tadalafil > sildenafil.
40                                              Vardenafil has higher affinity to phosphodiesterase-5 (P
41 nt study assessed the safety and efficacy of vardenafil in men with erectile dysfunction and untreate
42 hosphodiesterase-5 inhibitors sildenafil and vardenafil induces a parallel release of Abeta due to a
43  analogs demonstrated that higher potency of vardenafil is caused by differences in its double ring.
44                    Unlike in humans, in whom vardenafil is more potent than tadalafil, the relative p
45                These mutations fail to alter vardenafil (Levitra(R)) affinity for the active site.
46  mice with the phosphodiesterase-5 inhibitor vardenafil (Levitra) mobilized FoxO3a to the nucleus of
47 al administration of sildenafil (Viagra) and vardenafil (Levitra), inhibitors of cGMP-specific PDE5,
48 unrelated inhibitors, tadalafil (Cialis) and vardenafil (Levitra).
49 s (PDE-5i, such as Sildenafil, Tadalafil and Vardenafil, mainly prescribed to treat erectile dysfunct
50 terminal ends of Galpha(T) and the inhibitor vardenafil occupying the active sites on the PDEalpha an
51  addition, prolonged incubation of PDE6 with vardenafil or sildenafil (but not 3-isobutyl-1-methylxan
52 sk estimates were similar for sildenafil and vardenafil or tadalafil.
53 tions for the PDE5 inhibitors sildenafil and vardenafil or tadalafil.
54         Functional inhibition of ABCB1 using vardenafil or verapamil significantly (p <= 0.05-0.001)
55 and nonselective inhibitors, and that higher vardenafil potency over sildenafil and tadalafil results
56 6 amino acids in GAF-B are required for high vardenafil potency.
57                                              Vardenafil produced statistically significant and clinic
58 in, which forms bidentate bonds with 5'-GMP, vardenafil, sildenafil, and 3-isobutyl-1-methylxanthine
59                             For PDE5(Q817A), vardenafil, sildenafil, and IBMX inhibitory potencies we
60                 Change in affinity for cGMP, vardenafil, sildenafil, or IBMX in Y612F, H613A, L765A,
61          Catalytic-site affinities for cGMP, vardenafil, sildenafil, tadalafil, or 3-isobutyl-1-methy
62                  Affinity of V782A for cGMP, vardenafil, sildenafil, tadalafil, or IBMX was reduced 5
63 erapy agent, adriamycin, in combination with vardenafil survived significantly longer than rats treat
64 urthermore, a phosphodiesterase 5 inhibitor, vardenafil, synergizes with EGCG to induce cancer cell d
65 se-5 (PDE-5) inhibitors, such as sildenafil, vardenafil, tadalafil, mirodenafil, and udenafil, and ho
66 rugs for erectile dysfunction, tadalafil and vardenafil, trigger bone gain in mice through a combinat
67 ssion were observed in patients treated with vardenafil versus placebo.
68                               Treatment with vardenafil was the most important predictor for return t
69                                              Vardenafil was well tolerated and highly efficacious in
70 ed with vardenafil, due to steric clashes of vardenafil with a single methionine residue at position